Navigation Links
Intarcia Announces Appointment Of Dr. Sunita Zalani As Vice President, Global Head Of Regulatory Affairs And Quality

BOSTON, Aug. 5, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today officially announced the appointment of Sunita Zalani, Ph.D., as Vice President and Global Head of Regulatory Affairs and Quality. In her new capacity, Dr. Zalani serves on the Leadership Team and reports directly to Chairman, President & CEO Kurt Graves. The key new hire comes at a time when Intarcia is building out the company and 'rounding the corner' toward its first Phase 3 milestone later this year, with several others to follow in 2015. The role requires a proven leader with the ability to multi-task, to be results-oriented, to know how to avoid unnecessary risks, and the demonstrated ability to build highly productive and trust-based relationships with health authorities, partners, suppliers and other key stakeholders.

"We led a very competitive search for the person who would best meet the steep demands of our global regulatory and quality functions, and I'm delighted Intarcia prevailed as Sunita's choice out of several other simultaneous options she had," said Mr. Graves. "Sunita was our first choice almost immediately because of her proven leadership and operational experience in both large, and more recently, smaller biotech companies. She is a quick study, strategic, and impressively effective in a lean company environment. She gets difficult things done, and she gets them done extremely effectively and reliably. Her track record shows her to be a team leader with a 'gut grasp' of how to succeed in the biotech industry. Sunita also fits with our culture, our values, and the roll-up-your-sleeves energy required to be successful at Intarcia. This compatibility with our 'DNA' is vitally important. I'm confident that she will play a critical role in these exciting times as we move to strengthen the organization and build great relationships with health authorities and key partners in our mission to bring transformative new therapies to market for patients with type 2 diabetes, obesity and other serious diseases."

Just prior to joining Intarcia, Dr. Zalani worked at Onyx Pharmaceuticals as Vice President of Global Regulatory Affairs. Onyx, based in South San Francisco, is a subsidiary of Amgen. Dr. Zalani worked at Amgen's Thousand Oaks facilities in positions of increasing responsibility and importance since 2004. Prior to this, she worked at Eli Lilly and Company in Indianapolis, Indiana, exiting as their Global Regulatory Lead, Regulatory Affairs. During her career to date, Dr. Zalani's work has focused on therapeutic areas including: Endocrinology, Oncology, Nephrology, Cardiovascular, Inflammation, and Osteoporosis. She won numerous awards and distinctions while at Eli Lilly, she is well published, and has presented at industry and academic meetings. Dr. Zalani holds her Ph.D. in Biochemistry from the M.S. University of India, and was a Post-Doctoral Fellow and Research Fellow at the Lineberger Comprehensive Cancer Center at the University of North Carolina.

Mr. Graves added: "In her new role at Intarcia, Sunita will add great breadth and depth of expertise to a mission-critical area as she applies her skills and focused enthusiasm to get going on the numerous and diverse priorities ahead. This begins with the Company's first NDA filing, which is targeted for the end of 2015, and also extends to fully developing our European registration strategies, expediting our 12-month devices, and initiating additional planned studies to optimize our labeling and competitive differentiation. Through strong support and guidance in all of these areas, we believe Sunita can tangibly help make a bigger difference for the most people possible – a core aspiration of the people of Intarcia – which further facilitates our Company's ability to deliver value to all its stakeholders."

About ITCA 650

ITCA 650 (a once- or twice-yearly continuous subcutaneous delivery of exenatide) is being developed for the treatment of type 2 diabetes. The investigational therapy employs Intarcia's proprietary technology platform involving a matchstick-size, miniature osmotic pump that is inserted sub-dermally to provide continuous and consistent drug therapy, and the company's proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for extended periods of time.

Data from Intarcia's ITCA 650 Phase 2 program have demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the duration and severity of GI adverse events typically associated with the self-injection products in this class. ITCA 650 is an investigational new therapy and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. Upon approval, ITCA 650 would represent the first injection-free GLP-1 therapy that can deliver a full year of treatment from a single placement. Intarcia's robust intellectual property portfolio protects ITCA 650 through 2031. ITCA 650 is currently in a global phase 3 clinical trial program called FREEDOM, and some of the first available phase 3 results were reported at the JP Morgan conference in January of this year and viewed as very promising. Top-line results from the FREEDOM 1 and HBL phase 3 studies will be reported in September and/or October of this year. Further results will be reported later in 2014 and 2015.

About Intarcia Therapeutics, Inc.

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. In addition, delivering medicines just once or twice yearly virtually ensures patient adherence and compliance, which is very poor in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above-body temperature and to deliver them in a constant and consistent manner via Intarcia's proprietary technology platform. Intarcia is conducting a Phase 3-stage development program for type 2 diabetes and has additional programs ongoing for weight regulation to control obesity. For more information on the Company, please visit

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc.

Photo -

SOURCE Intarcia Therapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Intarcia Announces Expanded Appointment for Kurt Graves as Chairman, President and Chief Executive Officer
2. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
3. Intarcia Therapeutics Appoints Nancy Thornberry to Board of Directors
4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
5. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
6. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
7. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
8. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
9. WuXi PharmaTech Announces Third-Quarter 2011 Results
10. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
11. Spherix Announces Third Quarter Financial Results
Post Your Comments:
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT ... provide a corporate overview. th Annual Oppenheimer Healthcare ... ET/10:00 a.m. PT . Jim Mazzola , vice president ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... , Nov. 24, 2015  Clintrax Global, Inc., a worldwide ... Carolina , today announced that the company has set a ... a 391% quarter on quarter growth posted for Q3 of 2014 ... and Mexico , with the establishment of ... December 2015. --> United Kingdom and ...
(Date:11/24/2015)... November 24, 2015 --> ... research report released by Transparency Market Research, the global ... a CAGR of 17.5% during the period between 2014 ... - Global Industry Analysis, Size, Volume, Share, Growth, Trends ... prenatal testing market to reach a valuation of US$2.38 ...
(Date:11/24/2015)... , ... November 24, 2015 , ... InSphero AG, the ... cell culture models, has promoted Melanie Aregger to serve as Chief Operating Officer. ... served on the management team and was promoted to Head of InSphero ...
Breaking Biology Technology:
(Date:11/4/2015)... November 4, 2015 --> ... report published by Transparency Market Research "Home Security Solutions Market ... Forecast 2015 - 2022", the global home security solutions market is ... by 2022. The market is estimated to expand at ... 2015 to 2022. Rising security needs among customers at ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, Inc., ... U.S. distribution of its DNA library preparation products, ... Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has ... preparation of NGS libraries for liquid biopsies--the analysis ... and prognostic applications in cancer and other conditions. ...
(Date:10/27/2015)... -- Munich, Germany , October ... automatically maps data from mobile eye tracking videos created ... that they can be quantitatively analyzed with SMI,s analysis ... , October 28-29, 2015. SMI,s Automated Semantic Gaze ... tracking videos created with SMI,s Eye Tracking Glasses ...
Breaking Biology News(10 mins):